These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9659887)

  • 21. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.
    Jang Y; Guzman LA; Lincoff AM; Gottsauner-Wolf M; Forudi F; Hart CE; Courtman DW; Ezban M; Ellis SG; Topol EJ
    Circulation; 1995 Nov; 92(10):3041-50. PubMed ID: 7586275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
    Hindy-François C; Bachelot-Loza C; Le Bonniec B; Grelac F; Dizier B; Godier A; Emmerich J; Gaussem P; Samama CM
    Thromb Haemost; 2010 Oct; 104(4):823-30. PubMed ID: 20664889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis.
    Arnljots B; Söderström T; Ezban M; Hedner U
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S145-8. PubMed ID: 10850581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
    Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
    Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
    Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
    J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
    Hedner U; Erhardtsen E
    Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome.
    Vincent JL; Artigas A; Petersen LC; Meyer C
    Crit Care Med; 2009 Jun; 37(6):1874-80. PubMed ID: 19384216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII.
    Goudemand J; Caron C; Dreyfus M; Sié P;
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):505-11. PubMed ID: 12851539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.
    Jilma B; Marsik C; Mayr F; Graninger MT; Taylor FB; Ribel MC; Erhardtsen E; Handler S; Eichler HG
    Clin Pharmacol Ther; 2002 Oct; 72(4):403-10. PubMed ID: 12386642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
    Orvim U; Barstad RM; Vlasuk GP; Sakariassen KS
    Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2188-94. PubMed ID: 7489241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
    Chi L; Gibson G; Peng YW; Bousley R; Brammer D; Rekhter M; Chen J; Leadley R
    J Thromb Haemost; 2004 Jan; 2(1):85-92. PubMed ID: 14717971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model.
    Bonhomme F; Lecompte T; Samama CM; Godier A; Fontana P
    Eur J Anaesthesiol; 2018 Mar; 35(3):208-214. PubMed ID: 29334511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of warfarin on thrombosis of the jugular veins of rabbits induced by prolonged stasis.
    Foschi D; Scagnol I; Radaelli E; Pace M; Trabucchi E
    Drugs Exp Clin Res; 1993; 19(4):183-8. PubMed ID: 8131714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
    Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
    Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model.
    Nicolaisen EM; Kristensen H; Kristensen A; Hedner U
    Thromb Haemost; 2002 May; 87(5):836-9. PubMed ID: 12038786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
    Erhardtsen E; Nilsson P; Johannessen M; Thomsen MS
    J Clin Pharmacol; 2001 Aug; 41(8):880-5. PubMed ID: 11504276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.